PSMD4 and hepatocellular carcinoma: However, the results of clinical trials assessing the combination of TACE and sorafenib in HCC patients were inconsistent, with 3 negative trials[27, 28, 29] and only 1 positive trial.[30] Considering that MCB1 silencing sensitized HCC cells to either TACE or targeted drugs, we next explored whether MCB1 was associated with the therapeutic effect of TACE plus sorafenib.